Biomed Central Ltd

SHERPA: Unknown

People

  1. Autio
    Autio

Groups

  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Solid Tumor Oncology Division (11)
Search Within
  1. "Karen Autio"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (4)
Groups
  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Solid Tumor Oncology Division (11)
People
  1. Karen Autio (11)
Years
  1. 2023 (2)
  2. 2022 (2)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (1)
  6. 2018 (1)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (11)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Autio, K. A.; Higano, C. S.; Nordquist, L.; Appleman, L. J.; Zhang, T.; Zhu, X. H.; Babiker, H.; Vogelzang, N. J.; Prasad, S. M.; Schweizer, M. T.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
    Journal Article

    Postel-Vinay, S.; Lam, V. K.; Ros, W.; Bauer, T. M.; Hansen, A. R.; Cho, D. C.; Stephen Hodi, F.; Schellens, J. H. M.; Litton, J. K.; Aspeslagh, S.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 porter platform trial in metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Shotts, K.; Howes, T.; Yu, J.; Densmore, J.; Da Silva, D.; Kumar, D.; Santulli-Marotto, S.; Cabanski, C.; Eisenbeisz, E.; Ivison, G.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Clinical and pharmacodynamic biomarker results from porter, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Galsky, M.; Autio, K.; Wentzel, K.; Graff, J.; Friedlander, T.; Densmore, J.; Cabanski, C.; Shotts, K.; Howes, T.; Yu, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): An open-label dose-finding and first-in-human study
    Journal Article

    Naing, A.; Thistlethwaite, F.; de Vries, E. G. E.; Eskens, F. A. L. M.; Uboha, N.; Ott, P. A.; LoRusso, P.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): A first-in-human, dose-finding study
    Journal Article

    Sanborn, R. E.; Hamid, O.; de Vries, E. G. E.; Ott, P. A.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; Autio, K. A.; Cho, D. C.; Plummer, R.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Phase 1 study of AMG 160, a half-life extended BiTE(R) (Bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Dorff, T.; Rettig, M.; Machiels, J. P.; Lolkema, M.; Autio, K.; Greil, R.; Rottey, S.; Adra, N.; Salvati, M.; Poon, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • A multicenter, open-label, exploratory platform study to evaluate biomarkers and immunotherapy combinations for the treatment of patients with metastatic castration-resistant prostate cancer (PORTER)
    Meeting Abstract

    Nissola, L.; Autio, K.; Bhardwaj, N.; Galsky, M.; Wentzel, K.; Lucey, V.; Selinsky, C.; Perry, C.; Cabanski, C.; Bitton, A.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial
    Meeting Abstract

    Lyman, S. K.; Gordon, J.; DuPage, A.; Pramanik, P.; Howng, B.; Winter, M. B.; Popova, I. K.; Vasiljeva, O.; Jones, J.; Wong, K.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Immune activation by PEGylated human IL-10 (AM0010) and anti-tumor activity in renal cancer alone and in combination with anti-PD-1
    Meeting Abstract

    Naing, A.; Papadopoulos, K. P.; Autio, K. A.; Wong, D. J.; Patel, M.; Falchook, G.; Pant, S.; Ott, P. A.; Whiteside, M.; Patnaik, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save